gcpii

GCPII-IN-1 is a potent inhibitor scaffold targeting glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA). It exhibits a high affinity for GCPII, with a binding affinity (K i ) of 44.3 nanomolar (nM).

2-PMPA (2-(Phosphonomethyl)pentanedioic acid) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) (IC50=300 pM).

GCPII-IN-1 TFA is a scaffold inhibitor of glutamate carboxypeptidase II (GCPII; PSMA) with a Ki of 44.3 nM.

2-MPPA (GPI-5693) is an orally active, selective, and potent inhibitor of glutamate carboxypeptidase II (GCP II) (IC50: 90 nM) and also a NAALADase inhibitor, used in the study of neurological diseases.

PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.